Galmed Pharmaceuticals (GLMD) Return on Capital Employed (2014 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly Return on Capital Employed of 11.94% for Q2 2024, down 1321.0% year-over-year from 0.98% in Q3 2023, and down 52.52% quarter-over-quarter from 25.15% in Q2 2023.
Galmed Pharmaceuticals (GLMD) Return on Capital Employed (2014 - 2024) Analysis & Trends
Galmed Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 11.94% for Q2 2024.
- In Q2 2024, Return on Capital Employed fell 1321.0% year-over-year to 11.94%; the TTM figure through Jun 2024 stood at 11.94% (down 1321.0% YoY), while the FY2025 annual figure was 26.42%, down 2341.0% from the prior year.
- Return on Capital Employed for Q2 2024 stood at 11.94%, down from 25.15% in the prior quarter.
- The five-year high for Return on Capital Employed was 875.17% in Q3 2020, with the low at 1685.62% in Q2 2022.
- The 5-year median for Return on Capital Employed is 8.5% (2022), against an average of 51.34%.
- The sharpest annual moves came in 2021 and 2023: Return on Capital Employed sank 87237 bps in 2021, then surged 171077 bps in 2023.
- Galmed Pharmaceuticals' Return on Capital Employed stood at 0.02% in 2020, then soared by 18634 bps to 2.8% in 2021, then soared by 81 bps to 5.07% in 2022, then soared by 396 bps to 25.15% in 2023, then plunged by 53 bps to 11.94% in 2024.
- Business Quant data shows GLMD's Return on Capital Employed at 11.94% in Q2 2024, 25.15% in Q2 2023, and 5.07% in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 7.88% |
| 10 | Galmed Pharmaceuticals | 2.32 Mn | -9.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 11.94% |
| Jun 30, 2023 | 25.15% |
| Sep 30, 2022 | 5.07% |
| Jun 30, 2022 | -1,685.62% |
| Sep 30, 2021 | 2.80% |
| Mar 31, 2021 | -10.05% |
| Dec 31, 2020 | -0.02% |
| Sep 30, 2020 | 875.17% |
| Jun 30, 2020 | 135.06% |
| Mar 31, 2020 | 127.08% |
| Dec 31, 2019 | 115.73% |
| Sep 30, 2019 | 4.86% |
| Jun 30, 2019 | 5.56% |
| Mar 31, 2019 | 10.88% |
| Dec 31, 2018 | 8.94% |
| Sep 30, 2018 | 8.26% |
| Jun 30, 2018 | 17.75% |
| Mar 31, 2018 | 77.32% |
| Dec 31, 2017 | 115.75% |
| Sep 30, 2017 | 200.19% |